文献速递中医内科中药与中成药合理使用

血府逐瘀口服液治疗紧张型头痛的随机临床试验

Effect of Xuefu zhuyu oral liquid on tension-type headache: A randomized clinical trial.
PubMed 文献 · Phytomedicine · 2024-10-05

多中心双盲随机安慰剂对照试验纳入174例紧张型头痛患者,血府逐瘀口服液治疗4周。全分析集VAS变化与安慰剂无显著差异(-0.29,95%CI 0.81~0.23,p=0.279),符合方案集有显著差异(-0.9,95%CI -1.47~-0.33,p=0.002),次要结局均无显著差异,不良事件发生率相似。

要点

  • 全分析集中血府逐瘀口服液未显著改善头痛强度。
  • 符合方案集显示VAS有显著改善,需谨慎解读。
  • 次要结局及不良事件发生率与安慰剂相似。

核心结论

  • 血府逐瘀口服液可能成为高依从性紧张型头痛患者的镇痛替代选择,但全分析集未改善头痛指标。

主要发现

  • 全分析集VAS从基线至治疗结束平均变化组间差异为-0.29(95%CI 0.81~0.23,p=0.279),无统计学意义。
  • 符合方案集VAS平均变化组间差异为-0.9(95%CI -1.47~-0.33,p=0.002),有统计学意义。
  • 所有次要结局均无显著差异,两组不良事件发生率相似。

关键数值与推荐

  • 主要结局为VAS从基线至第4周平均头痛强度的变化。
  • 次要结局包括VAS从基线至第12周变化、头痛曲线下面积、应答率、头痛天数、平均头痛持续时间、急救药物使用比例等。

临床怎么用

  • 对于高依从性的紧张型头痛患者,可考虑血府逐瘀口服液作为镇痛替代选择,但需告知全分析集证据未显示显著获益。

局限性

  • 全分析集主要结局无显著差异,符合方案集结果需谨慎解读;次要结局均无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tension-type headache (TTH) is the most common neurological disorder worldwide, incurring immense social and economic costs and affecting quality of life. However, due to adverse reactions and inadequate effectiveness, there is still an unmet need for treatment. Xuefu zhuyu oral liquid (XZOL) is a Chinese patent medicine widely used for TTH in China, but evidence of its efficacy remains scant. PURPOSE: The aim of this study was to assess the efficacy and safety of XZOL for TTH patients. METHODS: This multicenter, double-blind, randomized placebo-controlled trial enrolled 174 patients with TTH in six centers in China from March 2020 to October 2021. Patients were randomly assigned to receive XZOL or a matched placebo for 4weeks. The primary outcome was the change in the mean headache intensity as measured by a visual analogue scale (VAS) from baseline to the end of treatment (Week 4). Secondary outcomes were the change in VAS from baseline to Week 12, the area-under-the-headache curve (AUC), response rate, number of headache days, average headache duration, rescue medication use proportion, etc. RESULTS: Of the 174 patients who were randomized, 160 completed the study. There was no significant difference in the mean change in VAS from baseline to the end of treatment between the XZOL group and the placebo group (-0.29; (95 % CI:0.81 to 0.23; p = 0.279) in the full analysis set (FAS), while there were statistically significant results (-0.9; 95 % CI:1.47 to -0.33; p = 0.002) in the per-protocol set (PPS). There were no significant differences in any of the secondary outcomes. The incidence of adverse events was similar in the two groups. CONCLUSION: XZOL may be an alternative option to relieve pain for TTH patients with high compliance in clinical practice. However, XZOL did not improve headache measurements in the FAS population.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Zhou L, Tan J, Li G, et al. Effect of Xuefu zhuyu oral liquid on tension-type headache: A randomized clinical trial. Phytomedicine. 2024. PMID: 39395325. doi:10.1016/j.phymed.2024.156112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。